Glenmede Trust’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $809K | Sell |
4,050
-432
| -10% | -$85.5K | ﹤0.01% | 805 |
|
|
2025
Q4 | $847K | Buy |
+4,482
| New | +$861K | ﹤0.01% | 769 |
|
|
2021
Q3 | – | Sell |
-3,677
| Closed | -$300K | – | 1317 |
|
|
2021
Q2 | $300K | Sell |
3,677
-80
| -2% | -$6.66K | ﹤0.01% | 1032 |
|
|
2021
Q1 | $357K | Sell |
3,757
-2,750
| -42% | -$260K | ﹤0.01% | 934 |
|
|
2020
Q4 | $403K | Buy |
6,507
+560
| +9% | +$31.9K | ﹤0.01% | 896 |
|
|
2020
Q3 | $352K | Buy |
5,947
+667
| +13% | +$45.5K | ﹤0.01% | 883 |
|
|
2020
Q2 | $368K | Buy |
5,280
+1,332
| +34% | +$84.4K | ﹤0.01% | 843 |
|
|
2020
Q1 | $256K | Hold |
3,948
| – | – | ﹤0.01% | 1101 |
|
|
2019
Q4 | $256K | Buy |
3,948
+328
| +9% | +$21.9K | ﹤0.01% | 1101 |
|
|
2019
Q3 | $224 | Sell |
3,620
-2,018
| -36% | -$127K | ﹤0.01% | 1127 |
|
|
2019
Q2 | $400 | Buy |
5,638
+351
| +7% | +$25.9K | ﹤0.01% | 965 |
|
|
2019
Q1 | $413 | Sell |
5,287
-443,832
| -99% | -$33.6M | ﹤0.01% | 936 |
|
|
2018
Q4 | $38K | Buy |
449,119
+166,595
| +59% | +$17.8M | 0.19% | 159 |
|
|
2018
Q3 | $48.4M | Sell |
282,524
-287,544
| -50% | -$43.4M | 0.19% | 160 |
|
|
2018
Q2 | $73.7M | Sell |
570,068
-59,802
| -9% | -$6.67M | 0.33% | 70 |
|
|
2018
Q1 | $53.8M | Hold |
629,870
| – | – | 0.22% | 119 |
|
|
2017
Q4 | $53.8M | Buy |
629,870
+128,304
| +26% | +$11.1M | 0.22% | 119 |
|
|
2017
Q3 | $42.6M | Buy |
501,566
+500,373
| +41,942% | +$39.6M | 0.19% | 162 |
|
|
2017
Q2 | $78K | Hold |
1,193
| – | – | ﹤0.01% | 1452 |
|
|
2017
Q1 | $78K | Buy |
1,193
+74
| +7% | +$4.87K | ﹤0.01% | 1452 |
|
|
2016
Q4 | $70K | Hold |
1,119
| – | – | ﹤0.01% | 1498 |
|
|
2016
Q3 | $71K | Buy |
1,119
+48
| +4% | +$3.52K | ﹤0.01% | 1484 |
|
|
2016
Q2 | $79K | Sell |
1,071
-255
| -19% | -$18.9K | ﹤0.01% | 1419 |
|
|
2016
Q1 | $87K | Buy |
1,326
+222
| +20% | +$13.5K | ﹤0.01% | 1359 |
|
|
2015
Q4 | $73K | Hold |
1,104
| – | – | ﹤0.01% | 1446 |
|
|
2015
Q3 | $58K | Buy |
1,104
+62
| +6% | +$3.76K | ﹤0.01% | 1539 |
|
|
2015
Q2 | $64K | Buy |
1,042
+75
| +8% | +$4.09K | ﹤0.01% | 1546 |
|
|
2015
Q1 | $46K | Hold |
967
| – | – | ﹤0.01% | 1712 |
|
|
2014
Q4 | $32K | Buy |
967
+209
| +28% | +$6.8K | ﹤0.01% | 1881 |
|
|
2014
Q3 | $22K | Sell |
758
-80
| -10% | -$2.65K | ﹤0.01% | 1932 |
|
|
2014
Q2 | $32K | Buy |
838
+521
| +164% | +$21.1K | ﹤0.01% | 1754 |
|
|
2014
Q1 | $13K | Hold |
317
| – | – | ﹤0.01% | 1990 |
|
|
2013
Q4 | $10K | Hold |
317
| – | – | ﹤0.01% | 1993 |
|
|
2013
Q3 | $8K | Hold |
317
| – | – | ﹤0.01% | 1969 |
|
|
2013
Q2 | $7K | Buy |
+317
| New | +$5.7K | ﹤0.01% | 1930 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Glenmede Trust's LGND Position: Q1 2026 in Review
Glenmede Trust reduced its Ligand Pharmaceuticals (LGND) stake by 9.6% in Q1 2026, selling an estimated $85.5K and leaving 4,050 shares worth $809K. The position accounts for ﹤0.01% of the portfolio, ranked #805.
Glenmede Trust first reported a position in LGND in Q2 2013 and has held it in 35 quarters since. The position peaked at $73.7M in Q2 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Glenmede Trust held 4,050 shares of Ligand Pharmaceuticals worth $809K as of Q1 2026.
- Glenmede Trust sold 432 Ligand Pharmaceuticals shares in Q1 2026, an estimated $85.5K.
- Ligand Pharmaceuticals made up ﹤0.01% of Glenmede Trust's portfolio in Q1 2026, its #805 holding.
- Glenmede Trust first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 35 quarters since.
- Glenmede Trust's Ligand Pharmaceuticals position peaked at $73.7M in Q2 2018.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.